| A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress PM Bruno, Y Liu, GY Park, J Murai, CE Koch, TJ Eisen, JR Pritchard, ... Nature medicine 23 (4), 461-471, 2017 | 453 | 2017 |
| Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform JM Rock, FF Hopkins, A Chavez, M Diallo, MR Chase, ER Gerrick, ... Nature microbiology 2 (4), 1-9, 2017 | 438 | 2017 |
| Defining principles of combination drug mechanisms of action JR Pritchard, PM Bruno, LA Gilbert, KL Capron, DA Lauffenburger, ... Proceedings of the National Academy of Sciences 110 (2), E170-E179, 2013 | 178 | 2013 |
| ARTIST: high-resolution genome-wide assessment of fitness using transposon-insertion sequencing JR Pritchard, MC Chao, S Abel, BM Davis, C Baranowski, YJ Zhang, ... PLoS genetics 10 (11), e1004782, 2014 | 162 | 2014 |
| Exploiting temporal collateral sensitivity in tumor clonal evolution B Zhao, JC Sedlak, R Srinivas, P Creixell, JR Pritchard, B Tidor, ... Cell 165 (1), 234-246, 2016 | 142 | 2016 |
| High-resolution definition of the Vibrio cholerae essential gene set with hidden Markov model–based analyses of transposon-insertion sequencing data MC Chao, JR Pritchard, YJ Zhang, EJ Rubin, J Livny, BM Davis, ... Nucleic acids research 41 (19), 9033-9048, 2013 | 132 | 2013 |
| The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning PM Bruno, M Lu, KA Dennis, H Inam, CJ Moore, J Sheehe, SJ Elledge, ... Proceedings of the National Academy of Sciences 117 (8), 4053-4060, 2020 | 127 | 2020 |
| Addressing genetic tumor heterogeneity through computationally predictive combination therapy B Zhao, JR Pritchard, DA Lauffenburger, MT Hemann Cancer discovery 4 (2), 166-174, 2014 | 113 | 2014 |
| Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus L Laencina, V Dubois, V Le Moigne, A Viljoen, L Majlessi, J Pritchard, ... Proceedings of the National Academy of Sciences 115 (5), E1002-E1011, 2018 | 104 | 2018 |
| Understanding resistance to combination chemotherapy JR Pritchard, DA Lauffenburger, MT Hemann Drug Resistance Updates 15 (5-6), 249-257, 2012 | 103 | 2012 |
| A mammalian functional-genetic approach to characterizing cancer therapeutics H Jiang, JR Pritchard, RT Williams, DA Lauffenburger, MT Hemann Nature chemical biology 7 (2), 92-100, 2011 | 100 | 2011 |
| An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor‐α BD Cosgrove, C Cheng, JR Pritchard, DB Stolz, DA Lauffenburger, ... Hepatology 48 (1), 276-288, 2008 | 90 | 2008 |
| Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors T Baker, S Nerle, J Pritchard, B Zhao, VM Rivera, A Garner, F Gonzalvez Oncotarget 6 (32), 32646, 2015 | 72 | 2015 |
| A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth CE Meacham, LN Lawton, YM Soto-Feliciano, JR Pritchard, BA Joughin, ... Genes & development 29 (5), 483-488, 2015 | 70 | 2015 |
| Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer CM Dowling, KER Hollinshead, A Di Grande, J Pritchard, H Zhang, ... Science advances 7 (3), eabc4897, 2021 | 37 | 2021 |
| Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in Philadelphia-positive leukemias MW Schmitt, JR Pritchard, SM Leighow, BI Aminov, L Beppu, DS Kim, ... Clinical Cancer Research 24 (21), 5321-5334, 2018 | 34 | 2018 |
| Predicting cancer drug mechanisms of action using molecular network signatures JR Pritchard, PM Bruno, MT Hemann, DA Lauffenburger Molecular bioSystems 9 (7), 1604-1619, 2013 | 34 | 2013 |
| Disruption of Mycobacterium avium subsp. paratuberculosis-specific genes impairs in vivo fitness J Wang, JR Pritchard, L Kreitmann, A Montpetit, MA Behr BMC genomics 15, 1-10, 2014 | 29 | 2014 |
| Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL NJ Short, H Kantarjian, R Kanagal-Shamanna, K Sasaki, F Ravandi, ... Blood cancer journal 10 (5), 61, 2020 | 28 | 2020 |
| RET fusions observed in lung and colorectal cancers are sensitive to ponatinib JM Gozgit, TH Chen, Y Song, S Wardwell, F Wang, J Cai, H Li, H Edgren, ... Oncotarget 9 (51), 29654, 2018 | 28 | 2018 |
Boyang ZhaoQuantalarity (Principal Scientist), ING (Manager Data Science), MIT (PhD)Verified email at mit.edu
